被誉为“减肥药双雄”的诺和诺德,周五给全球投资者表演了一把“高位跳水”。由于备受期待的“下一代减肥药”数据不佳,截至发稿公司美股盘前一度下跌超20%——基本把2023年7月以后的涨幅全部回吐了。(诺和诺德日线图)诺和诺德周五官网发布的公告显示,备受期待的复方合剂CagriSema(2.4毫克卡格列肽+2.4毫克司美格鲁肽),在试验对象坚持使用68周后,CagriSema组平均减重22.7%。作为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.